RxDoctor Payments Data

Ronald Frenkel, MD

Ophthalmology · Stuart, FLNPI 1649280553

Payments from drug & device makers

What this record shows

21 manufacturers reported payments, led by Alcon at 54.8% of the total. Reporting peaked in 2023 at $2,358 and has fallen 88.5% since, to $271 in 2025.

$3,873in general payments, 2019–2025

Across 77 payments — averaging $50.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Regeneron Healthcare Solutions, Inc.$419
  • Genentech USA, Inc.$236
  • Apellis Pharmaceuticals, Inc.$216
  • AbbVie$207
  • Aerie Pharmaceuticals, Inc.$81
  • plus $595 from 15 others
$2,057,670in research payments, 2019–2025

Across 474 payments — averaging $4341.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$484K
  • Regeneron$451K
  • AbbVie$392K
  • Apellis Pharmaceuticals, Inc.$255K
  • Hexal AG$122K
  • Boehringer Ingelheim International GmbH$113K
  • plus $241K from 7 others

What the payments were for

  • Travel & lodging$1,91149%
  • Food & beverage$1,96251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,873 in reported general payments places this provider in the 65th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$340,187
Medicare patients
395
Services billed
4,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost65$31,416
RestasisCyclosporine14$14,807
Alphagan PBrimonidine Tartrate25$14,297
RhopressaNetarsudil Mesylate18$8,228
VyzultaLatanoprostene Bunod14$7,275
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol25$5,595
Brimonidine Tartrate98$4,346
Prednisolone Acetate115$3,490
Travoprost17$3,452
Latanoprost239$3,169
Ketorolac Tromethamine121$2,941
Timolol Maleate131$2,927
Dorzolamide-TimololDorzolamide/Timolol/Pf12$2,454
Gatifloxacin59$2,118
Brinzolamide11$1,963

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P$207$60,520104 claims
Aerie Pharmaceuticals, Inc.Rhopressa$81$8,22818 claims
Bausch & Lomb Americas Inc.Vyzulta$61$7,27514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Stuart

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →